Device Trial Radar · NCT07944794
Safety and Effectiveness of Different Interface Models for Non-invasive Ventilation Support for Preterm Newborns With a Gestational Age Greater Than or Equal to 28 Weeks.
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Sep 19, 2025
Primary completion
Nov 30, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- University of Sao Paulo General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 28 weeks, up to 36 weeks
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized, stratified clinical trial by gestational age with 5 arms including preterm newborns (PTNBs) with a gestational age (GA) ≥ 28 weeks, in a public hospital in northeastern Brazil. * There is no difference in efficacy and safety between the 5 interfaces. * To describe the differences in efficacy and safety of the 5 interfaces. After signing the informed consent form, stratification will be performed by gestational age (≥ 28 weeks and \< 32 weeks, and ≥ 32 weeks and \< 37 weeks). After respiratory assessment, if mild to moderate respiratory distress (BSA between 1 and 6) is confirmed. Following randomization for allocation to the groups, eligible newborns who had multiple births will be randomized individually. Those who use mechanical ventilation and who will be extubated will be randomized following the same inclusion criteria. Patients will be randomly allocated into 5 groups according to the NIV interface: * Group 1 (G1) - Infant Flow LP® Interface; * Group 2 (G2) - RAM® Cannula; * Group 3 (G3) - Dräger Babyflow® Nasal Mask; * Group 4 (G4) - Conventional binasal prongs (Ventcare®); * Group 5 (G5) - Fanem® Flexible Anatomical Binosal Prongs. Randomization will be done using sequentially numbered, sealed, opaque envelopes containing the group allocation, separated into two boxes as per the stratification described above. Vital signs and blood pressure will be collected before the use of ventilatory support on a specific data collection form and will continue at 4-hour intervals at the following times (8:00, 12:00, 16:00, 20:00, 0:00, 4:00) until non-invasive ventilation is withdrawn.
Conditions
- Respiratory Distress Syndrome in Premature Infants
- Non Invasive Ventilation (NIV)
- Nasal Injury
Interventions
Infant FlowDevice
Infant Flow LP non-invasive ventilation interface
Ram CannulaDevice
Ram Cnnula non-invasive ventilation interface
Baby Flow nasal maskDevice
Baby flow nasal mask non-invasive ventilation interface
Conventional binasal prongsDevice
Conventional binasal prongs non-invasive ventilation interface
Fanem Flexible Anatomical Binaural ProngsDevice
Fanem Flexible Anatomical Binaural Prongs non-invasive ventilation interface
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Non-Invasive Ventilation (NIV) FailureTime frame: From enrollment (Day 1) up to NIV discontinuation or hospital discharge, whichever occurs first, assessed up to 60 days (an average of 14 days).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fundação Hospitalar de Feira de Santana
Feira de Santana, Estado de Bahia, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.